XML 52 R32.htm IDEA: XBRL DOCUMENT v3.26.1

Segment Reporting (Tables)

12 Months Ended

Dec. 31, 2025

Segment Reporting [Abstract]

Schedule of Reconciliation Consolidated Net Loss

The following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s consolidated net loss.

 Schedule of Reconciliation Consolidated Net Loss 

		Pharmaceuticals								Computing Technology
		2025				2024				2025				2024
Sales			-				-				-				-
Product Cost of Sales			-				-				-				-
Gross Income			-				-				-				-
Operating Expenses
Administrative Expenses			2,013,710				4,161,907				1,722,816				-
Research and Development Expenses			3,045,977				3,441,010				425,864				-
Stock-Based Compensation			1,937,691				-				236,833
Franchise Tax Expense			150,038				-				50,013				-
Warrant Issuance Expense			-				-				264,417				-
Segment Net Loss			(7,147,415	)			(7,602,917	)			(2,699,942	)			-
Reconcilement of Net Loss
Adjustments and Reconciling Items
Stock Based Compensation			1,325,144				1,057,271				-				-
Series F Warrant Issuance Expenses			-				-				-				-
Series F-1 Warrant Issuance Expenses			-				539,097				-				-
Series G Warrant Issuance Expenses			-				969,505				-				-
Series H Warrant Issuance Expenses			-				-				264,417				-
Dividends Paid on Series H Preferred Stock			-				-				99,437				-
Interest and Dividend Income			156,042				351,809				69,346				-
Gains on Sales of Marketable Securities			2,176				976				-				-
Unrealized Gains on Marketable Securities			(1,435	)			671				40,106				-
Change in Fair Value of Derivative Liabilities			1,303,000				(388,000	)			(320,000	)			-
Change in Fair Value of Warrant Liabilities			-				(4,410,000	)			-				-
Loss on Issuance of Series F-1 Convertible Preferred Stock			-				(3,737,000	)			-				-
Loss on Issuance of Series G Convertible Preferred Stock			-				(5,109,000	)			-				-
Loss on Impairment of Intangible			(1,500,000	)			-				-				-
Loss on FMV of Contingent Compensation			-				-				(1,529,000	)			-
Casualty Gain/(Loss)			-				100,000				-				-
Total Adjustments and Reconciling Items			(1,365,331	)			(15,756,417	)			(2,103,402	)			-
Consolidated Net Loss		$	(5,782,084	)		$	(23,359,334	)			(596,540	)			-

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration